Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Sun, Hong
TSL-CM-JSSPMFSL-Ⅲ, NCT06068465: A Study of the Safety and Efficacy of Pimavanserin in Patients with Parkinson's Disease Psychosis	Recruiting	3	248	RoW	pimavanserin tartrate, placebo	Tasly Pharmaceutical Group Co., Ltd	Parkinson's Disease Psychosis	06/25	01/26
PRESERVE-003, NCT05671510: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors	Active, not recruiting	3	600	Europe, Canada, US, RoW	Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere	OncoC4, Inc., BioNTech SE	Non Small Cell Lung Cancer	06/26	06/27
Zhang, Zhixiang
PRESERVE-003, NCT05671510: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors	Active, not recruiting	3	600	Europe, Canada, US, RoW	Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere	OncoC4, Inc., BioNTech SE	Non Small Cell Lung Cancer	06/26	06/27